Subscribe to RSS
DOI: 10.1055/s-2006-939715
Efficient Microwave-Assisted Synthesis of Tetrahydroindazoles and their Oxidation to Indazoles
Publication History
Publication Date:
22 May 2006 (online)
![](https://www.thieme-connect.de/media/synlett/200609/lookinside/thumbnails/10.1055-s-2006-939715-1.jpg)
Abstract
N-Acetyl-styrylpyrazoles undergo Diels-Alder cycloaddition reactions with N-methylmaleimide under solvent-free conditions to give the corresponding tetrahydroindazoles in good yields and high selectivity. On heating, these reactions do not occur or afford only traces of the cycloadducts. The stereochemistry of obtained cycloadducts was assigned by NMR. Oxidation of the tetrahydroindazoles with DDQ gave the expected indazoles and was accompanied by N-deacylation.
Key words
4-styrylpyrazoles - Diels-Alder cycloadditions - microwave irradiation - N-methylmaleimide - indazoles - dehydrogenation
-
1a
Elguero J. Pyrazoles and their Benzo Derivatives, In Comprehensive Heterocyclic Chemistry Vol. 5:Potts KT.Katritzky AR.Rees CW. Pergamon Press; Oxford: 1984. p.167-303 -
1b
Elguero J. Pyrazoles, In Comprehensive Heterocyclic Chemistry II Vol. 3:Shinkai I.Katritzky AR.Rees CW.Scriven EFV. Pergamon Press; Oxford: 1996. p.1-75 - 2
O’Neil MJ.Smith A. The 13th Merck Index Merck Research Laboratories Division of Merck & Co. Inc.; Whitehouse Station, New York: 2001. -
3a
Bistocchi GA.De Meo G.Pedini M.Ricci A.Brouilhet H.Bucherie S.Rabaud M.Jacquignon P. Farmaco Ed. Sci. 1981, 36: 315 -
3b
Picciola G.Ravenna F.Carenini G.Gentili P.Riva M. Farmaco Ed. Sci. 1981, 36: 1037 -
3c
Mosti L.Sansebastiano L.Fossa P.Schenone P.Mattioli F. Il Farmaco 1992, 47: 357 -
3d
Gordon DW. Synlett 1998, 1065 -
3e
Schindler R.Hoefgen N.Heinecke K.Poppe H.Szelenyi I. Pharmazie 2000, 55: 857 -
4a
Lóránd T.Kocsis B.Emôdy L.Sohár P. Eur. J. Med. Chem. 1999, 1009 -
4b
Stefańska JZ.Gralewska R.Starościak BJ.Kazimierczuk Z. Pharmazie 1999, 54: 879 -
5a
Sun J.-H.Teleha CA.Yan J.-S.Rodgers JD.Nugiel DA. J. Org. Chem. 1997, 62: 5627 -
5b
Rodgers JD.Jonhson BL.Wang H.Greenberg RA.Erickson-Viitanen S.Klabe RM.Cordova BC.Rayner MM.Lam GN.Chang C.-H. Bioorg. Med. Chem. Lett. 1996, 6: 2919 - 6
Keppler BK.Hartmann M. Met.-Based Drugs 1994, 1: 145 -
7a
Bland-Ward PA.Moore PK. Life Sci. 1995, 57: 131 -
7b
Mamiya T.Noda Y.Noda A.Hiramatsu M.Karasawa K.Kameyama T.Furukawa S.Yamada K.Nabeshima T. Neuropharmacology 2000, 39: 2391 -
7c
Schumann P.Collot V.Hommet Y.Gsell W.Dauphin F.Sopkova J.MacKenzie ET.Duval D.Boulouard M.Rault S. Bioorg. Med. Chem. Lett. 2001, 11: 1153 - 8
Raman CS.Li H.Martásek P.Southan G.Masters BSS.Poulos TL. Biochemistry 2001, 40: 13448 - 9
Connolly PJ.Wetter SK.Beers KN.Hamel SC.Haynes-Johnson D.Kiddoe M.Kraft P.Lai MT.Campen C.Palmer S.Phillips A. Bioorg. Med. Chem. Lett. 1997, 7: 2551 - 10
Mosti L.Menozzi G.Fossa P.Schenone P.Lampa E.Parrillo C.Damico M.Rossi F. Il Farmaco 1992, 47: 567 -
11a
Behr LC.Fusco R.Jarboe CH. Pyrazoles, Pyrazolines, Pyrazolidines, Indazoles and Condensed RingsWiley RH. Interscience Publishers; New York: 1967. -
11b
Baiocchi L.Corsi G.Palazzo G. Synthesis 1978, 633 -
12a
Medio-Simón M.Laviada MJA.Sepúlveda-Arques J. J. Chem. Soc., Perkin Trans. 1 1990, 2749 -
12b
Sepúlveda-Arques J.Abarca-González B.Medio-Simón M. Adv. Heterocycl. Chem. 1995, 63: 339 - 13
Matsugo S.Takamizawa A. Synthesis 1983, 852 - 14
Tomé AC.Cavaleiro JAS.Storr RC. Synlett 1996, 531 -
15a
Pinto DCGA.Silva AMS.Cavaleiro JAS. Heterocycl. Commun. 1997, 3: 433 -
15b
Pinto DCGA.Silva AMS.Cavaleiro JAS.Foces-Foces C.Llamas-Sainz AL.Jagerovic N.Elguero J. Tetrahedron 1999, 55: 10187 -
15c
Pinto DCGA.Silva AMS.Lévai A.Cavaleiro JAS.Patonay T.Elguero J. Eur. J. Org. Chem. 2000, 2593 -
15d
Pinto DCGA.Silva AMS.Cavaleiro JAS. J. Heterocycl. Chem. 2000, 37: 1629 -
15e
Lévai A.Patonay T.Silva AMS.Pinto DCGA.Cavaleiro JAS. J. Heterocycl. Chem. 2002, 39: 751 -
15f
Silva VLM.Silva AMS.Pinto DCGA.Cavaleiro JAS.Elguero J. Eur. J. Org. Chem. 2004, 4348 -
18a
Pinto DCGA.Silva AMS.Almeida LMPM.Carrillo JR.Díaz-Ortiz A.de la Hoz A.Cavaleiro JAS. Synlett 2003, 1415 -
18b
Pinto DCGA.Silva AMS.Brito CM.Sandulache A.Carrillo JR.Prieto P.Díaz-Ortiz A.de la Hoz A.Cavaleiro JAS. Eur. J. Org. Chem. 2005, 2973 - 20
Silva AMS.Pinto DCGA.Cavaleiro JAS.Lévai A.Patonay T. Arkivoc 2004, (vii): 106 - 28
Lévai A.Silva AMS.Pinto DCGA.Cavaleiro JAS.Alkorta I.Elguero J.Jekö J. Eur. J. Org. Chem. 2004, 4672
References and Notes
Physical Data of (
E
)-1-(1-Methyl-2,5-dioxo-3-pyrrol-idinyl)-5-styryl-3-(2-hydroxyphenyl)pyrazole (
1d).
Mp 234-236 °C. 1H NMR (300.13 MHz, CDCl3): δ = 3.13 (s, 3 H, NCH
3), 3.30 (dd, 1 H, J = 18.3, 9.1 Hz, 4′′′-CH
2), 3.45 (dd, 1 H, J = 18.3, 5.2 Hz, 4′′′-CH
2), 5.46 (dd, 1 H, J = 9.1, 5.2 Hz, 3′′′-CH), 6.90 (s, 1 H, H-4), 6.96 (ddd, 1 H, J = 7.7, 7.3, 1.2 Hz, H-5′), 7.00 (dd, 1 H, J = 8.4, 1.2 Hz, H-3′), 7.01 (d, 1 H, J = 15.8 Hz, H-α), 7.22-7.27 (m, 1 H, H-4′), 7.26 (d, 1 H, J = 15.8 Hz, H-β), 7.35-7.44 (m, 3 H, H-3′′,5′′,4′′), 7.53 (dd, 2 H, J = 8.1, 1.5 Hz, H-2′′,6′′), 7.59 (dd, 1 H, J = 7.7, 1.7 Hz, H-6′), 10.03 (s, 1 H, 2′-OH). 13C NMR (75.47 MHz, CDCl3): δ = 25.5 (NCH
3), 34.8 (4′′′-CH2), 55.6 (3′′′-CH), 100.8 (C-4), 112.6 (C-α), 115.8 (C-1′), 117.1 (C-3′), 119.5 (C-5′), 126.6 (C-6′), 126.9 (C-2′′,6′′), 128.9 (C-3′′,5′′), 129.1 (C-4′′), 129.9 (C-4′), 135.6 (C-1′′), 136.1 (C-β), 143.9 (C-5), 152.5 (C-3), 155.7 (C-2′), 173.3 (2′′′-C=O), 172.5 (5′′′-C=O). MS (EI): m/z (rel. int.) = 374 (30), 373 (100) [M+
•], 372 (25), 262 (39), 261 (67), 231 (11), 202 (10), 155 (5), 128 (6), 115 (16), 91 (29), 77 (9), 65 (9).
Physical Data of (
E
)-3-(2-Hydroxyphenyl)-1-methyl-5-styrylpyrazole (
1b).
Mp 159-161 °C. 1H NMR (300.13 MHz, CDCl3): δ = 3.92 (s, 3 H, 1-CH3), 6.81 (s, 1 H, H-4), 6.89 (ddd, 1 H, J = 7.9, 7.3, 1.1 Hz, H-5′), 6.91 (d, 1 H, J = 16.2 Hz, H-α), 7.02 (dd, 1 H, J = 8.0, 1.1 Hz, H-3′), 7.13 (d, 1 H, J = 16.2 Hz, H-β), 7.21 (ddd, 1 H, J = 8.0, 7.3, 1.6 Hz, H-4′), 7.32 (dd, 2 H, J = 7.6, 6.8 Hz, H-3′′,5′′), 7.39 (tt, 1 H, J = 7.6, 1.6 Hz, H-4′′), 7.51 (dd, 2 H, J = 6.8, 1.6 Hz, H-2′′,6′′), 7.57 (dd, 1 H, J = 7.9, 1.6 Hz, H-6′), 10.82 (s, 1 H, 2′-OH). 13C NMR (75.47 MHz, CDCl3): δ = 36.6 (1-CH3), 98.9 (C-4), 113.7 (C-α), 116.5 (C-1′), 117.0 (C-3′), 119.2 (C-5′), 126.1 (C-6′), 126.7 (C-2′′,6′′), 128.6 (C-4′′), 128.8 (C-3′′,5′′), 129.0 (C-4′), 133.5 (C-β), 136.0 (C-1′′), 141.8 (C-5), 150.2 (C-3), 155.8 (C-2′). MS (EI): m/z (rel. int.) = 276 (100) [M+•
], 275 (20), 231 (5), 202 (7), 185 (10), 144 (14), 128 (10), 115 (20), 102 (8), 91 (11), 77 (15). Anal. Calcd for C18H16N2O: C, 78.24; H, 5.84; N, 10.14. Found:C, 77.84; H, 5.79; N, 10.02.
Typical Experimental Procedure.
Acetyl chloride (1 mol equiv) was added to a stirred solution of (E)-3-(2-hydroxyphenyl)-5-styrylpyrazole (1a) in dry pyridine. The mixture was stirred at r.t. and under nitrogen atmosphere until complete disappearance of the starting 5-styrylpyrazole 1a. After that period the reaction mixture was poured over ice and H2O, and acidified at pH 2 with a 10% solution of HCl. The resulting mixture was extracted with CHCl3 and dried over anhyd Na2SO4. The solvent was evaporated to dryness and the residue purified by thin layer chromatography with CH2Cl2 as eluent giving the expected (E)-1-acetyl-3-(2-hydroxyphenyl)-5-styrylpyrazole (1c) in moderate yield (44%). Mp 124.4-126.2 °C. 1H NMR (300.13 MHz, CDCl3): δ = 2.77 (s, 3 H, 1-COCH
3), 6.98 (ddd, 1 H, J = 7.7, 7.5, 1.1 Hz, H-5′), 7.06 (s, 1 H, H-4), 7.07 (dd, 1 H, J = 8.3, 1.1 Hz, H-3′), 7.22 (d, 1 H, J = 16.5 Hz, H-β), 7.30-7.43 (m, 4 H, H-4′,3′′,4′′,5′′), 7.57 (d, 2 H, J = 7.7 Hz, H-2′′,6′′), 7.63 (dd, 1 H, J = 7.7, 1.6 Hz, H-6′), 7.93 (d, 1 H, J = 16.5 Hz, H-α), 10.38 (s, 1 H, 2′-OH). 13C NMR (75.47 MHz, CDCl3): δ = 24.0 (1-COCH3), 104.0 (C-4), 114.8 (C-1′), 116.4 (C-α), 117.3 (C-3′), 119.6 (C-5′), 127.2 (C-2′′,6′′), 127.4 (C-6′), 128.8 (C-3′′,5′′), 129.0 (C-4′′), 131.0 (C-4′), 135.6 (C-β), 136.0 (C-1′′), 145.8 (C-5), 153.9 (C-3), 156.5 (C-2′), 170.8 (1-COCH3). MS (EI): m/z (rel. int.) = 304 (80) [M+•], 262 (73) [M - C2H2O]+, 245 (5), 233 (5), 216 (4), 202 (6) [M - C8H6]+, 191 (2), 185 (21) [M - C7H5NO]+, 178 (4), 171 (100), 155 (3), 140 (4), 128 (5), 115 (23), 102 (6), 89 (5), 77 (8) [C6H5
+], 65 (4). Anal. Calcd for C19H16N2O2: C, 74.98; H, 5.30; N, 9.20. Found: C, 75.01; H, 5.26; N, 9.05.
Physical Data of (
E
)-1-Acetyl-4-(4-chlorostyryl)-3-(2-hydroxyphenyl)pyrazole (
5b).
Mp 169.1-169.9 °C. 1H NMR (300.13 MHz, CDCl3): δ = 2.76 (s, 3 H, 1-COCH
3), 6.94 (AB, 1 H, J = 16.1 Hz, H-β), 6.99 (dd, 1 H, J = 7.5, 6.9 Hz, H-5′), 7.04 (AB, 1 H, J = 16.1 Hz, H-α), 7.12 (dd, 1 H, J = 8.3, 1.1 Hz, H-3′), 7.33-7.36 (m, 1 H, H-4′), 7.36 (d, 2 H, J = 8.6 Hz, H-3′′5′′), 7.42 (d, 2 H, J = 8.6 Hz, H-2′′,6′′), 7.62 (dd, 1 H, J = 7.5, 1.6 Hz, H-6′), 8.47 (dd, 1 H, J = 0.7 Hz, H-5), 9.82 (s, 1 H, 2′-OH). 13C NMR (75.47 MHz, CDCl3): δ = 21.6 (1-COCH3), 115.9 (C-1′), 117.4 (C-3′), 117.9 (C-α), 119.8 (C-5′), 122.9 (C-4), 126.2 (C-5), 127.8 (C-2′′,6′′), 128.9 (C-6′), 129.0 (C-3′′,5′′), 130.9 (C-4′), 131.3 (C-β), 133.9 (C-4′′), 135.0 (C-1′′), 152.4 (C-3), 156.0 (C-2′), 168.1 (1-COCH3). MS (EI): m/z (rel. int.) = 340 (36) [M+•
, 37Cl], 338 (81) [M+•
, 35Cl], 298 (35), 296 (81), 281 (5), 267 (4), 260 (8), 242 (4), 231 (6), 202 (8), 185 (20), 171 (100), 149 (5), 115 (14), 102 (6), 77 (4). Anal. Calcd for C19H15ClN2O2: C, 67.36; H, 4.46; N, 8.27. Found: C, 67.48; H, 4.73; N, 8.30.
Physical Data of (
Z
)-1-Acetyl-4-(4-chlorostyryl)-3-(2-hydroxyphenyl)pyrazole (
6b).
Mp 141.8-143.6 °C. 1H NMR (300.13 MHz, CDCl3): δ = 2.72 (s, 3 H, 1-COCH
3), 6.50 (dd, 1 H, J = 11.9, 1.1Hz, H-α), 6.75 (d, 1 H, J = 11.9 Hz, H-β), 6.95 (ddd, 1 H, J = 7.2, 7.9, 1.2 Hz, H-5′), 7.09 (dd, 1 H, J = 8.3, 1.2 Hz, H-3′), 7.17-7.23 (m, 4 H, H-2′′,3′′,5′′,6′′), 7.33 (ddd, 1 H, J = 7.2, 8.3, 1.6 Hz, H-4′), 7.87 (dd, 1 H, J = 7.9, 1.6 Hz, H-6′), 8.00 (d, 1 H, J = 1.1 Hz, H-5), 10.23 (s, 1 H, 2′-OH). 13C NMR (75.47 MHz, CDCl3): δ = 21.6 (1-COCH3), 115.7 (C-1′), 117.3 (C-3′), 119.6 (C-5′), 119.9 (C-α), 120.0 (C-4), 127.6 (C-5), 128.5 (C-6′), 128.7 (C-2′′,6′′), 129.8 (C-3′′,5′′), 131.0 (C-4′), 132.4 (C-β), 133.5 (C-4′′), 134.4 (C-1′′), 153.1 (C-3), 156.3 (C-2′), 167.8 (C=O). MS (EI): m/z (rel. int.) = 340 (31) [M+•
, 37Cl], 338 (69) [M+•
, 35Cl], 298 (32), 296 (71), 281 (5), 260 (8), 231 (7), 202 (8), 185 (22), 171 (100), 149 (6), 115 (17), 102 (8), 89 (5), 77 (7). Anal. Calcd for C19H15ClN2O2: C, 67.36; H, 4.46; N, 8.27. Found: C, 67.15; H, 4.37; N, 7.98.
Optimised Experimental Procedure.
A mixture of (E or Z)-1-acetyl-3-(2-hydroxyphenyl)-4-styrylpyrazoles 5a-d or 6a-c and N-methylmaleimide (1:6 mole ratio) was irradiated at atmospheric pressure in an Ethos SYNTH microwave (Milestone Inc.), at 800 W for 40 min. The crude product was dissolved in CHCl3 and purified by thin layer chromatography with a 8:2 mixture of CHCl3-EtOAc as eluent. The residue was crystallised from EtOH to give the expected 1-acetyl-3-(2-hydroxyphenyl)-7-methyl-5-phenyl-6,8-dioxopyrrolo[3,4-g]-5,5a,8a,8b-tetrahydro-indazoles (7a, 88%; 7b, 68%; 7c, 95%; 7d, 95%; 8a, 32%; 8b, 54%; 8c, 54%).
Physical Data of 1-Acetyl-5-(4-ethoxyphenyl)-3-(2-hydroxyphenyl)-7-methyl-6,8-dioxopyrrolo[3,4-
g
]-5,5a,8a,8b-tetrahydroindazole (
7c).
Mp 236-237 °C. 1H NMR (300.13 MHz, CDCl3): δ = 1.44 (t, 3 H, J = 7.0 Hz, 4′′-OCH2CH
3), 2.54 (s, 3 H, 1-COCH
3), 2.76 (s, 3 H, 7-CH
3), 3.37 (dd, 1 H, J = 8.5, 7.4 Hz, H-5a), 3.54 (br dd, 1 H, J = 7.4, 4.5 Hz, H-5), 4.07 (dq, 2 H, J = 7.0, 1.9 Hz, 4′′-OCH
2CH3), 4.46 (dd, 1 H, J = 8.5, 7.1 Hz, H-8a), 4.97 (br dd, 1 H, J = 7.1, 3.6 Hz, H-8b), 6.94 (dd, 1 H, J = 4.5, 3.6 Hz, H-4), 6.96 (d, 2 H, J = 8.6 Hz, H-3′′,5′′), 6.97 (ddd, 1 H, J = 8.6, 7.2, 0.9 Hz, H-5′), 7.10 (dd, 1 H, J = 8.0, 0.9 Hz, H-3′), 7.21 (d, 2 H, J = 8.6 Hz, H-2′′,6′′), 7.38 (ddd, 1 H, J = 8.0, 7.2, 1.4 Hz, H-4′), 7.66 (dd, 1 H, J = 8.6, 1.4 Hz, H-6′), 9.85 (s, 1 H, 2′-OH). 13C NMR (75.47 MHz, CDCl3): δ = 14.9 (4′′-OCH2
CH3), 21.5 (1-COCH3), 25.0 (7-CH3), 40.6 (C-8a), 42.1 (C-5a), 44.5 (C-5), 57.5 (C-8b), 63.5 (4′′-OCH2CH3), 114.4 (C-1′), 114.5 (C-3′′,5′′), 117.7 (C-3′), 119.7 (C-5′), 126.2 (C-4), 127.5 (C-6′;), 129.0 (C-1′′), 129.8 (C-2′′,6′′), 131.9 (C-4′), 137.8 (C-3a), 149.3 (C-3), 157.1 (C-2′), 158.5 (C-4′′), 168.6 (1-COCH3), 173.4 (C-6), 174.5 (C-8). MS (EI): m/z (rel. int.) = 459 (52) [M+•
], 417 (28), 348 (100), 306 (70), 277 (18), 257 (10), 171 (35), 160 (7), 91 (10). Anal. Calcd for C29H25N3O5: C, 67.96; H, 5.48; N, 9.14. Found: C, 67.80; H, 5.49; N, 8.76.
Physical Data of 1-Acetyl-5-(4-ethoxyphenyl)-3-(2-hydroxyphenyl)-7-methyl-6,8-dioxopyrrolo[3,4-
g
]-5,5a,8a,8b-tetrahydroindazole (
8c).
Mp 244-245 °C. 1H NMR (300.13 MHz, CDCl3): δ = 1.42 (t, 3 H, J = 7.0 Hz, 4′′-OCH2CH
3), 2.46 (s, 3 H, 1-COCH
3), 2.89 (s, 3 H, 7-CH
3), 3.56 (br d, 1 H, J = 8.6 Hz, H-5a), 4.70 (br d, 1 H, J = 7.6 Hz, H-5), 4.02 (dq, 2 H, J = 7.0 Hz, 4′′-OCH
2CH3), 4.42 (dd, 1 H, J = 8.6, 8.0 Hz, H-8a), 4.80 (dd, 1 H, J = 8.0, 3.8 Hz, H-8b), 6.96 (dd, 1 H, J = 7.6, 3.8 Hz, H-4), 6.88 (d, 2 H, J = 8.7 Hz, H-3′′,5′′), 6.98 (ddd, 1 H, J = 7.6, 7.4, 1.0 Hz, H-5′), 7.09 (dd, 1 H, J = 8.2, 1.0 Hz, H-3′), 7.23 (d, 2 H, J = 8.7 Hz, H-2′′,6′′), 7.37 (ddd, 1 H, J = 8.2, 7.4, 1.5 Hz, H-4′), 7.70 (dd, 1 H, J = 7.6, 1.5 Hz, H-6′), 9.81 (s, 1 H, 2′-OH). 13C NMR (75.47 MHz, CDCl3): δ = 14.8 (4′′-OCH2
CH3), 21.5 (1-COCH3), 25.3 (7-CH3), 41.5 (C-8a), 41.8 (C-5), 43.0 (C-5a), 55.7 (C-8b), 63.6 (4′′-OCH2CH3), 114.3 (C-1′), 115.2 (C-3′′,5′′), 117.6 (C-3′), 119.7 (C-5′), 125.9 (C-4), 127.6 (C-6′), 127.9 (C-2′′,6′′), 128.2 (C-1′′), 131.8 (C-4′), 138.2 (C-3a), 149.6 (C-3), 157.0 (C-2′), 158.3 (C-4′′), 168.4 (1-COCH3), 173.9 (C-6), 177.7 (C-8). MS (EI): m/z (rel. int.) = 459 (46) [M+•
], 417 (29), 348 (14), 306 (42), 295 (100), 282 (14), 210 (21), 171 (36), 135 (16), 77 (5). Anal. Calcd for C29H25N3O5: C, 67.96; H, 5.48; N, 9.14. Found: C, 67.91; H, 5.45; N, 9.16.
Optimised Experimental Procedure.
A mixture of each of the appropriate 1-acetyl-3-(2-hydroxyphenyl)-7-methyl-5-phenyl-6,8-dioxopyrrolo[3,4-g]-5,5a,8a,8b-tetrahydroindazoles 7a,b,d or 8c and DDQ (1:3 mol ratio) in 1,2,4-trichlorobenzene was irradiated at atmospheric pressure in an Ethos SYNTH microwave (Milestone Inc.), at 800 W for 30 min. The crude product was purified by column chromatography, using light PE as eluent, to remove the 1,2,4-trichlorobenzene, followed by EtOAc to remove the reaction product, which was further purified by TLC with a 9:1 mixture of CHCl3-EtOAc as eluent. The residue was recrystallised from EtOH to give 5-aryl-3-(2-hydroxyphenyl)-7-methyl-6,8-dioxopyrrolo[3,4-g]indazoles (9a from 7a, 85%; 9b from 7b, 32%; 9c from 8c, 31%; 9d from 7d, 34%).
Physical Data of 3-(2-Hydroxyphenyl)-7-methyl-5-phenyl-6,8-dioxopyrrolo[3,4-
g
]indazole (
9a).
Mp >275 °C. 1H NMR (300.13 MHz, CDCl3): δ = 3.21 (s, 3 H, NCH
3), 7.05 (ddd, 1 H, J = 7.7, 7.6, 1.2 Hz, H-5′), 7.16 (dd, 1 H, J = 8.1, 1.2 Hz, H-3′), 7.36 (ddd, 1 H, J = 7.6, 8.1, 1.6 Hz, H-4′), 7.48-7.61 (m, 4 H, H-2′′,3′′,5′′,6′′), 8.02 (dd, 1 H, J = 7.7, 1.6 Hz, H-6′), 8.44 (s, 1 H, H-4), 10.47 (s, 1 H, NH), 11.27 (s, 1 H, 2′-OH). 13C NMR (75.47 MHz, CDCl3): δ = 24.0 (NCH3), 116.2 (C-1′), 117.7 (C-3′), 119.8 (C-5′), 130.2 (C-4), 127.3 (C-6′), 128.2 (C-2′′,6′′), 129.7 (C-3′′,5′′), 130.5 (C-4′), 128.5 (C-4′′), 133.1 (C-8b), 136.6 (C-5,1′′), 145.7 (C-3), 156.3 (C-2′), 133.4 (C-3a), 128.2 (C-5a), 116.5 (C-8a), 167.9 (C-6,8). MS (EI): m/z (rel. int.) = 369 (100) [M+•
], 326 (3), 311 (3), 284 (5), 255 (5), 226 (4), 164 (3), 91 (2).